Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL125967 | 1.00 | BCL2L1 (0.35) | BCL2L1USP2POLBCHRM2CHRM4 | |
| Chloromethane SCHEMBL3872398 | 0.96 | BCL2L1 (0.37) | BCL2L1USP2 | |
| SCHEMBL36879 | 0.88 | USP2 (0.37) | USP2 | |
| SCHEMBL3670018 | 0.88 | USP2 (0.37) | USP2 | |
| SCHEMBL33998 | 0.88 | USP2 (0.37) | USP2 | |
| SCHEMBL3670015 | 0.88 | USP2 (0.37) | USP2 | |
| SCHEMBL3108917 | 0.86 | ALDH1A1 (0.37) | USP2 | |
| Hydrochloric Acid SCHEMBL8410448 | 0.86 | USP2 (0.36) | USP2 | |
| Bromide SCHEMBL3232032 | 0.86 | USP2 (0.36) | USP2 | |
| SCHEMBL3295908 | 0.86 | ALDH1A1 (0.37) | USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025097070-A1 | ORAL DOSAGE FORM WITH CATIONICALLY CHARGEABLE HYDROGEL FOR DELIVERY OF ACTIVE AGENT | ENTREGA INC. (US) | 2025-05-08 | — | — | WO | claimed |
| WO-2017092951-A1 | DOMAIN PARTICLES OF PESTICIDE PARTICLES EMBEDDED IN AN IONIC ACRYLATE COPOLYMER | BASF SE (DE) | 2017-06-08 | — | — | WO | claimed |
| EP-2248780-A1 | Set- and hardening accelerator | BK Giulini GmbH (DE) | 2010-11-10 | — | — | EP | claimed |
| EP-1530600-B1 | BIO-SYNTHETIC MATRIX AND USES THEREOF | OTTAWA HEALTH RESEARCH INST (CA) | 2007-03-14 | — | — | EP | claimed |
| US-20060217285-A1 | Controlled structure copolymer comprising an amphoteric or zwitterionic part | RHODIA CHIMIE (FR) | 2006-09-28 | — | — | US | claimed |
| US-20060134050-A1 | Bio-synthetic matrix and uses thereof | FORSKARPATENT I LINKOPING AB (SE) | 2006-06-22 | — | — | US | claimed |
| US-20060034807-A1 | Innervated artificial tissues and uses thereof | OTTAWA HEALTH RESEARCH INSTITUTE | 2006-02-16 | — | — | US | claimed |
| WO-2025097070-A1 | ORAL DOSAGE FORM WITH CATIONICALLY CHARGEABLE HYDROGEL FOR DELIVERY OF ACTIVE AGENT | ENTREGA INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025046201-A1 | POLYOL FOR DELAYING GAS HYDRATE FORMATION | ARKEMA FRANCE (FR) | 2025-03-06 | — | — | WO | disclosed |
| EP-3714007-B1 | ANTIFOULING COMPOSITION | JOTUN AS (NO) | 2024-08-21 | — | — | EP | disclosed |
| CN-111479882-B | Antifouling composition | 佐敦有限公司 | 2022-04-19 | — | — | CN | disclosed |
| US-10798940-B2 | Penflufen polymer particles | LANXESS DEUTSCHLAND GMBH (DE) | 2020-10-13 | — | — | US | disclosed |
| EP-3714007-A1 | ANTIFOULING COMPOSITION | Jotun A/S (NO) | 2020-09-30 | — | — | EP | disclosed |
| EP-0322891-A2 | Multilayered packaging materials having high gas barrier property | KURARAY CO., LTD. (JP) | 1989-07-05 | — | — | EP | disclosed |
| US-4668360-A | Process for electrocoating water reducible quaternary ammonium salt containing polymers | THE SHERWIN-WILLIAMS COMPANY (US) | 1987-05-26 | — | — | US | disclosed |
| US-4561952-A | Water reducible quaternary ammonium salt containing polymers | THE SHERWIN-WILLIAMS COMPANY (US) | 1985-12-31 | — | — | US | disclosed |
| EP-0132678-A1 | Copolymers of methyl esters of N-vinyl-carbamic acid | BAYER AG (DE) | 1985-02-13 | — | — | EP | disclosed |
| US-4444954-A | WITH ACTIVE HYDROGEN-CONTAINING MONOMER AND A BLOCKED POLYISOCYANATE | THE SHERWIN-WILLIAMS COMPANY (US) | 1984-04-24 | — | — | US | disclosed |
| US-4420541-A | QUATERNARY AMMONIUM SALT OF TERT-AMINOALKYL ACRYLATE OR ACRYLAMIDE AND AN ORGANIC HALIDE | THE SHERWIN-WILLIAMS COMPANY (US) | 1983-12-13 | — | — | US | disclosed |
| US-4322331-A | Radiation polymerizable compounds and conductive coatings from same | THE SHERWIN-WILLIAMS COMPANY (US) | 1982-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060034807-A1 | Innervated artificial tissues and uses thereof | NGF, GAP43, NTRK2 | BCL2L1 1467/4885USP2 1712/4885POLB 3483/4885 |
| US-10798940-B2 | Penflufen polymer particles | FAP, PUF60, MATR3 | BCL2L1 4650/4885USP2 1407/4885POLB 1092/4885 |
| US-20060134050-A1 | Bio-synthetic matrix and uses thereof | MMP1, HDGF, COL2A1 | BCL2L1 400/4885USP2 2539/4885POLB 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.